Compare Nasdaq Inc (NDAQ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Summit Therapeutics Inc — how do they compare? Nasdaq Inc trades at $94.39 (market cap $53.13B), while Summit Therapeutics Inc trades at $17.55 (market cap $13.79B). The key difference: Nasdaq Inc is far larger — about 3.9× Summit Therapeutics Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NDAQ | SMMT | |
|---|---|---|
Market Cap | $53.13B | $13.79B |
Sector | Financials | Health |
52-Week High | $100.98 | $26.38 |
52-Week Low | $76.85 | $12.43 |
Enterprise Value | $59.58B | $13.11B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.04, down 1.9% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, up from $7.4B in 2024, and net income margin improved to 22.52%. Recent news highlights Nasdaq's acquisition of Dasseti to enhance AI capabilities in investment technology.
The outlook for NDAQ is positive, supported by consistent earnings outperformance, revenue growth, and strategic acquisitions. Risks include market volatility and competitive pressures. Analysts maintain a bullish consensus with a $109.20 price target, implying 15% upside from current levels.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
